by PEPID Newsroom | Mar 6, 2019 | Alerts
Measles, also known as rubeola or “first disease”, is a highly contagious viral infection caused by paramyxovirus, causing a prodrome of fever, cough, coryza, and conjunctivitis followed by eruption of maculopapular rash. The CDC states 2 main reasons for the increase...
by PEPID Newsroom | Feb 27, 2019 | Alerts
CDC published a report today that provides the most recent data on HIV trends in America from 2010 to 2016. The results show a stagnation in the decline of HIV infections, with numbers of HIV Infections leveling off at about 39,000. When taking a deeper dive into the...
by PEPID Newsroom | Feb 13, 2019 | Emergency Medicine, Nursing, Pharmacy, Primary Care
Founder and CEO, Mark Rosenbloom, MD, MBA joins PEPID Pulse’s Implementing Precision Medicine live broadcast series at HIMSS 2019. Dr. Rosenbloom’s talk, “Implementing Precision Medicine in the Clinical Setting: Challenges and Rewards” expounds on: Pharmacogenomics’...
by PEPID Newsroom | Feb 12, 2019 | Press & Media
PEPID, a leading global innovator in point-of-care technologies for the healthcare industry worldwide continued their success announcing the introduction of its cutting-edge Pharmacogenomics tool, named PEPID PGx. It is now showcasing at HIMSS 2019 this week. PEPID...
by PEPID Newsroom | Jan 28, 2019 | Alerts
Public Officials in Clark County, Washington are investigating a measles outbreak after reports of 34 confirmed cases and nine suspected cases since the first of January. Of the 34 cases, thirty-two have been confirmed to be unimmunized, while four remain unverified....
by PEPID Newsroom | Jan 7, 2019 | Press & Media
January 7, 2019 — Phoenix, AZ — Trusted medical information and point-of-care solutions provider, PEPID, LLC is pleased to announce another partnered advance towards patient-centered care. Moving forward with PEPID’s Bedside Education in Florida State University’s...
by PEPID Newsroom | Jan 2, 2019 | Alerts
The FDA has approved Elxonris (tagraxofusperzs) infusion to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients two years and older. This is the first FDA approved therapy specifically for BPDCN. Elzonris is a targeted investigational therapy...
by PEPID Newsroom | Jan 2, 2019 | Alerts
The injection Ultomirus (ravulizumab) has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is a long-acting complement inhibitor that prevents hemolysis. Richard Pazdur, M.D., director of the FDA’s Oncology...
by PEPID Newsroom | Dec 27, 2018 | Alerts
FDA approved ProAir digihaler by Asthmapolis, the first app-connected digital inhaler. The ProAir Digihaler has built-in sensors to detect when the device is used and the strength of the user’s inhalation. This data is then sent via Bluetooth to its mobile app...
by PEPID Newsroom | Dec 17, 2018 | Alerts
There’s a new drug for people suffering from Chronic Idiopathic Constipation(CIC) headed to the market in 2019. The US FDA has approved Motegrity with the active ingredient Prucalopride for the treatment of CIC presented by Shire Dev LLC. Motegrity is a...
